ISIS PHARMACEUTICAL (ISI BE) stock market data APIs
€63.8387
0(0%)
as of November 7, 2025
Try our APIs with
free plan!
ISIS PHARMACEUTICAL Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for ISI.BE.
Prev. Close
63.8387
Open
63.8387
High
63.8387
Low
63.8387
52 wk Range
22.5-64.38
Market Cap
3 685 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ISIS PHARMACEUTICAL data using free add-ons & libraries
Get ISIS PHARMACEUTICAL Fundamental Data
ISIS PHARMACEUTICAL Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-29
- EPS/Forecast: -1.05
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ISIS PHARMACEUTICAL News
New
Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions
– Up to 72% placebo-adjusted mean reduction in fasting triglyceride levels at six months, with reductions sustained through 12 months – – 86% of olezarsen-treated patients achieved triglyceride...
Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting
DAWNZERA showed durable efficacy, demonstrating 94% overall mean HAE attack rate reduction at one year in OASISplus open-label extension study Patients in OASISplus switch study achieved 68% improveme...
US$81.91 - That's What Analysts Think Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Is Worth After These Results
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) investors will be delighted, with the company turning in some strong numbers with its latest results. The results were impressive, with revenues of US$157m ex...
Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings.
Alnylam stock took a hit Thursday after the biotech company said it received a subpoena from the U.S. government related to its four drugs. Continue Reading View Comments
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
